Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Circadian Therapeutics has been established to identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.

© Shutterstock

Today, there are no safe, effective and fast-acting treatments that provide benefit to patients through modulation of circadian rhythms.

To address this, Circadian Therapeutics has identified drug candidates and is looking to study their effects on circadian rhythms in clinical trials. 

Circadian's intellectual property draws on the input of the Nuffield Department of Clinical Neurosciences, the Department of Pharmacology, and the Institute of Biomedical Engineering, and builds on research supported by the Wellcome Trust. 

Read more on the University of Oxford website...